Leveraging our proprietary LNP platform to advance RNA therapeutics and in vivo immune cell engineering programs.
Item-Listing separated by:
- Program
- Modality
- Routes of Administration
- Discovery Phase
- IND-Enabling Phase
- Phase I
- Phase II
- Partner
- Focus Area
-
Program
NA001
-
Modality
mRNA
Routes of Administration
Respiratory (Inhaled)
-
Discovery Phase
100% -
IND-Enabling Phase
100% -
Phase I
80% -
Phase II
0% -
Partner
Undisclosed
-
Focus Area
COPD
-
Program
NA002
-
Modality
mRNA
Routes of Administration
Parenteral (IV)
-
Discovery Phase
100% -
IND-Enabling Phase
15% -
Phase I
0% -
Phase II
0% -
Partner
Internal
-
Focus Area
Immunology
-
Program
NA003
-
Modality
RNA/Gene Engineering
Routes of Administration
Parenteral (IV)
-
Discovery Phase
100% -
IND-Enabling Phase
95% -
Phase I
0% -
Phase II
0% -
Partner
Undisclosed
-
Focus Area
in vivo NK cell engineering
-
Program
NA004
-
Modality
mRNA
Routes of Administration
Respiratory (Inhaled)
-
Discovery Phase
100% -
IND-Enabling Phase
100% -
Phase I
80% -
Phase II
0% -
Partner
Internal
-
Focus Area
COPD
-
Program
NA005
-
Modality
mRNA
Routes of Administration
Parenteral (IV)
-
Discovery Phase
100% -
IND-Enabling Phase
0% -
Phase I
0% -
Phase II
0% -
Partner
Company X
-
Focus Area
Immunology